Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06257485 · ClinicalTrials.gov registry record
Bronx Transthyretin Amyloid Cardiomyopathy Database
A clinical trial of Transthyretin Cardiac Amyloidosis and Transthyretin Amyloid Cardiomyopathy, sponsored by Montefiore Medical Center.
- Active
- Registry status
- 476
- Enrollment target
- 1
- Study location
NCT06257485 is a study of Transthyretin Cardiac Amyloidosis and Transthyretin Amyloid Cardiomyopathy that is active but no longer recruiting, run by Montefiore Medical Center. The registered enrollment target is 476 participants, roughly in line with the 517-participant average among 4 other Transthyretin Cardiac Amyloidosis trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT06257485, a study of Transthyretin Cardiac Amyloidosis and Transthyretin Amyloid Cardiomyopathy, is active but no longer recruiting, sponsored by Montefiore Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- 476 participants
- Enrollment target
- 1
- Study location
Study Summary
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a commonly undiagnosed and potentially fatal disease. Contemporary studies on this condition often underrepresent the female gender and diverse patient populations. This registry retrospectively evaluated patients referred for 99mTc-pyrophosphate (PYP) Single Photon Emission Computed Tomography (SPECT) between 2014 and 2023 at Montefiore-Einstein in the Bronx. The patient population is racially and ethnically diverse and with a high proportion of females. Demographic, clinical (e.g. comorbidities), laboratory, echocardiographic, hospitalization, and mortality data were collected for each patient.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST 99mTc-pyrophosphate Single Photon Emission Computed Tomography
Study Locations (1)
New York
- Montefiore Health System - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 476 participants |
| Start Date | 2023-09-23 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06257485
The ClinicalTrials.gov registry entry for NCT06257485 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 476 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 517-participant average among 4 other Transthyretin Cardiac Amyloidosis trials with a reported enrollment target. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Transthyretin Cardiac Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which 99mTc-pyrophosphate Single Photon Emission Computed Tomography is the first listed.
NCT06257485 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06257485 about?
NCT06257485 is a clinical study titled "Bronx Transthyretin Amyloid Cardiomyopathy Database". Transthyretin amyloid cardiomyopathy (ATTR-CM) is a commonly undiagnosed and potentially fatal disease. Contemporary studies on this condition often underrepresent the female gender and diverse patient populations. This registry retrospectively evaluated patients referred for 99mTc-pyrophosphate (PY...
What is the current status of trial NCT06257485?
This trial is currently active not recruiting. The enrollment target is 476 participants. The study started on 2023-09-23. Estimated completion is 2026-12.
What conditions does trial NCT06257485 study?
This clinical trial studies the following conditions: Transthyretin Cardiac Amyloidosis, Transthyretin Amyloid Cardiomyopathy.
What interventions are being tested in trial NCT06257485?
The interventions under investigation include: 99mTc-pyrophosphate Single Photon Emission Computed Tomography (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06257485?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06257485 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transthyretin Cardiac Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation
RECRUITING · Phase 4
-
Exercise Training in Transthyretin Cardiac Amyloidosis
RECRUITING · NA
-
Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis
RECRUITING
-
Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis
COMPLETED · Early Phase 1
Explore more on PlainTrial
Transthyretin Cardiac Amyloidosis
All registered trials for this condition
Transthyretin Amyloid Cardiomyopathy
All registered trials for this condition
New York
All trials with a study site in New York
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.